Given that PsP appearance is always preceded by treatment (Supplementary Table S8) and not all IDH mutant patients begin definitive therapy immediately after initial surgery, we repeated this analysis using the time from the start of each patient’s first definitive therapy (chemotherapy or RT) to PsP and TP to examine a more clinically relevant time interval. Here, IDH2 is linked to supranuclear palsy, progressive, 1.